Clinical trial
Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT
NCT02572492 is registered in ClinicalTrials.gov with Henrik Gregersen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT
- Lead sponsor
- Henrik Gregersen
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 31, 2015
- Completion date
- April 30, 2019
- Enrollment
- 200 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.